** Shares of biotech firm IMUNON IMNN.O rise 2% to $3.17

** Co says it will cut jobs and reduce expenses to shift more resources toward its late-stage study testing IMNN‑001 for ovarian cancer

** Ovarian cancer is often detected late; co’s experimental therapy aims to boost the body’s immune response at the tumor site - IMNN

** Co says its late-stage trial is enrolling patients ahead of schedule

** Recent mid-stage data showed IMNN‑001 plus standard chemo helped patients live a median 13 months longer than chemo alone, per co

** Co says chief scientific officer, Khursheed Anwer, will retire Feb. 20

** Shares up ~93% in 2025

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))